Source: Annual Congress 2011 - Progress in pathology of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Masuda, N. Hattori, K. Hamai, S. Akita, T. Senoo, H. Iwamoto, S. Ohshimo, M. Kanehara, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, N. Kohno (Hiroshima, Japan). SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor growth and lung metastasis formation probably through the reduction of tumor angiogenesis. Eur Respir J 2011; 38: Suppl. 55, 1479

Member's Comments

No comment yet.

Related content which might interest you: The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway Source: Annual Congress 2004 - Lung development and cancer Year: 2004 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L) Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Tumor-related angiogenesis: role in tumour growth and metastasis formation Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Influence of prostaglandin E2 on cell surface urokinase-type plasminogen activator expression and activity in lung adenocarcinoma cell line Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Benzamidine-type urokinase inhibitors reduce primary tumor growth in a Lewis lung carcinoma model Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Circulating fibrocytes depletion results in reduced lung tumor growth and metastasis by modulating macrophage phenotype, angiogenesis and endothelin system Source: ERS Lung Science Conference 2017 Year: 2017 PP133 – IGF1R acts in the tumor microenvironment as a cancer-promoting factor facilitating the implantation and progression of lung metastasis Source: ERS Lung Science Conference 2021 Year: 2021